During it’s 2019 Scientific Sessions, the National Lipid Association (NLA) released a statement paper, led by Dr. Jennifer Robinson, Immediate Past National Forum Board Chair. The paper provides updated guidance to clinicians with identifying patient groups in which use of PCSK9 monoclonal antibodies (mAbs) provides a reasonable value. Read the full press release here. Access the manuscript and other resources here.
Dr. Robinson also chairs the National Forum’s Value & Access initiative, designed to improve access to evidence-based cardiovascular care.